Summit Therapeutics PLC Company Profile (LON:SUMM)

Analyst Ratings

Consensus Ratings for Summit Therapeutics PLC (LON:SUMM) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Summit Therapeutics PLC (LON:SUMM)
Show:
DateFirmActionRatingPrice TargetActions
1/20/2016N+1 SingerReiterated RatingCorporateView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/2/2015JMP SecuritiesInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for Summit Therapeutics PLC (LON:SUMM)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Summit Therapeutics PLC (LON:SUMM)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Summit Therapeutics PLC (LON:SUMM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Summit Therapeutics PLC (LON:SUMM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/17/2015Valerie AndrewsInsiderBuy10,500GBX 145£15,225Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Summit Therapeutics PLC (LON:SUMM)
DateHeadline
06/22/16 09:58 AMSummit Therapeutics : Shows Further Positive Trial Data For Ridinilazole
06/22/16 09:58 AMSummit uses more than gut instinct to prove C.diff antibiotic's worth
06/21/16 11:09 AMFirst Quarter Financial Results - [at noodls] - Summit Corporation plc Summit Therapeutics plc‌‌‌‌‌‌ ("Summit" or the "Company") SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 30 APRIL 2016 AND OPERATIONAL ...
06/17/16 09:18 AMSummit Therapeutics : Enrols First Patient In Phase II Ezutromid Trial
06/17/16 09:18 AMSummit Therapeutics recruits first phase II DMD patient
06/10/16 06:59 PM5 Attractive Biotechnology Stocks For Healthy, Long-Term Returns
06/10/16 06:59 PMDuchenne Muscular Dystrophy Global Clinical Trials Review, H1, 2016 - New Market Research Report
06/02/16 06:07 AMQ1 2017 Summit Therapeutics PLC Earnings Release - Time Not Supplied -
05/31/16 07:02 PMCaldan Therapeutics bolsters senior team - Dr Armstrong brings extensive experience in the pharmaceutical industry to Caldan Therapeutics, and currently also serves as non-executive chairman of Summit plc and RedX Pharma. Prior to this, he led Merck's medical science and innovation division ...
02/26/16 12:32 PMSummit Therapeutics plc ( SUMM ) - SUMMIT THERAPEUTICS ANNOUNCES PUBLICATION OF PRECLINICAL DATA SHOWING RIDINILAZOLE OUTPERFORMED STANDARD OF CARE IN REDUCING C. DIFFICILE TOXINS THAT DRIVE DISEASE SYMPTOMS Oxford, UK, 24 February 2016 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM ...
02/24/16 06:00 AMSummit Therapeutics Announces Publication of Preclinical Data Showing Ridinilazole Outperformed Standard of Care in Reducing C. Difficile Toxins That Drive Disease Symptoms - [GlobeNewswire] - OXFORD, United Kingdom, Feb. 24, 2016-- Summit Therapeutics plc, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces ...
02/05/16 02:00 PMWill Edwards thought nothing of his own safety when he saw flames engulfing the car when it burst into flames on the M60 - Fireman wins Milk Tray Man role. weiterlesen ... Dazu schreibt newratings.com: Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS TO PRESENT AT 18(TH) ANNUAL BIO CEO & INVESTOR CONFERENCE Oxford, UK, 3 February 2016 - Summit ...
02/03/16 06:00 AMSummit Therapeutics to Present at 18th Annual BIO CEO & Investor Conference - [GlobeNewswire] - OXFORD, United Kingdom, Feb. 03, 2016-- Summit Therapeutics plc, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces ...
01/29/16 01:17 PMRecent Broker Updates On Summit Therapeutics Plc (SMMT) - Risers & Fallers - Recent Broker Updates On Summit Therapeutics Plc (SMMT)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Summit Therapeutics plc (SMMT). The latest broker reports which are currently outstanding on Friday 29th January state 0 analysts have a rating of “strong buy”, 0 analysts ...and more »
01/28/16 01:11 PMRecent Broker Updates On Summit Therapeutics (LON:SUMM) - Risers & Fallers - Recent Broker Updates On Summit Therapeutics (LON:SUMM)Risers & FallersSummit Therapeutics plc, formerly Summit Corporation plc, is a United Kingdom-based biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or ...and more »
01/26/16 01:15 PMOppenheimer Thinks Summit Therapeutics' Stock is Going to Recover - Analyst Ratings - Oppenheimer Thinks Summit Therapeutics' Stock is Going to RecoverAnalyst RatingsOppenheimer analyst Christopher Marai reiterated an Outperform rating on Summit Therapeutics (NASDAQ: SMMT) today and set a price target of $28. The company's shares closed last Friday at $8.70, close to its 52-week low of $8.10. Marai commented ...
01/22/16 07:15 PMSummit Therapeutics gets European patent for antibiotic ridinilazole to treat C. difficile infection - pharmabiz.com - Summit Therapeutics gets European patent for antibiotic ridinilazole to treat C. difficile infectionpharmabiz.comSummit Therapeutics plc, a drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection (CDI), announced that the European Patent Office (EPO) has granted a key patent covering the ...
01/22/16 12:13 PMSummit Therapeutics gets European patent for antibiotic ridinilazole to treat C. difficile infection - Summit Therapeutics plc, a drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection (CDI), announced that the European Patent Office (EPO) has granted a key patent covering the novel ...
01/21/16 12:26 PMPeptide Therapeutics Market Will Rise at a Moderate 2.8% CAGR to Touch US$23.7 ... - SYS-CON Media (press release) - Peptide Therapeutics Market Will Rise at a Moderate 2.8% CAGR to Touch US$23.7 ...SYS-CON Media (press release)In a recent research report published by Transparency Market Research (TMR), "the global peptide therapeutics market will be valued at US$23.7 bn by 2020, increasing from its 2013 valuation of US$18.9 bn. If the projected figure hold true, the market ...and more »
01/21/16 12:26 PMSummit Therapeutics Gets UK OK to Start Phase 2 Trial of Duchenne Muscular ... - WallStreet.org - Summit Therapeutics Gets UK OK to Start Phase 2 Trial of Duchenne Muscular ...WallStreet.orgSummit Therapeutics plc operates as a biopharmaceutical company primarily in the United Kingdom and the Unites States. It focuses on the discovery, development, and commercialization of novel medicines to treat the Duchenne Muscular Dystrophy (DMD), ...
01/21/16 12:26 PMAyretrade, Inc. (SUMM) Granted Key European Patent for Ridinilazole for Treatment of C. Difficile - Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. Summit Therapeutics plc (NASDAQ: SMMT) announces that the European Patent Office (‘EPO’) has granted a key patent covering the novel antibiotic, ridinilazole ...
01/21/16 12:26 PMSummit Therapeutics Receives Regulatory Approval to Initiate PhaseOut DMD, a Phase 2 Clinical Trial in DMD - 21 January 2016 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and Clostridium difficile infection, announces that it has received approval from ...
01/21/16 06:25 AMSummit Therapeutics Receives Regulatory Approval to Initiate PhaseOut DMD, a Phase 2 Clinical Trial of SMT C1100 in Patients With DMD - [at noodls] - 249a91f9-0226-4922-b924-13d819ea26d4.pdf Summit Therapeutics plc ("Summit" or "the Company") SUMMIT THERAPEUTICS RECEIVES REGULATORY APPROVAL TO INITIATE PhaseOut DMD, A PHASE 2 CLINICAL ...
01/20/16 12:11 PMSummit Therapeutics Granted Key European Patent - ag-IP-news Agency - Summit Therapeutics Granted Key European Patentag-IP-news AgencyOXFORD, UK - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection ('CDI'), announced in a press release that the ...
01/19/16 06:53 PMSummit Therapeutics Granted Key European Patent for Novel Antibiotic Ridinilazole for Treatment of C. Difficile ... - GlobeNewswire (press release) - Proactive Investors USA & CanadaSummit Therapeutics Granted Key European Patent for Novel Antibiotic Ridinilazole for Treatment of C. Difficile ...GlobeNewswire (press release)OXFORD, UK, Jan. 19, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection ('CDI'), ...Summit Therapeutics Gets European Patent For Antibiotic RidinilazoleLondon South East (registration) (blog)all 14 news articles »
01/19/16 11:46 AMSummit Therapeutics Granted Key European Patent for Novel Antibiotic ... - CNNMoney - Proactive Investors USA & CanadaSummit Therapeutics Granted Key European Patent for Novel Antibiotic ...CNNMoney19, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection ('CDI'), announces that the ...Summit Therapeutics Gets European Patent For Antibiotic RidinilazoleLondon South East (registration) (blog)all 11 news articles »
01/19/16 11:46 AMPrice Target Update On Summit Therapeutics Plc (SMMT) - Risers & Fallers - Price Target Update On Summit Therapeutics Plc (SMMT)Risers & FallersThe share price of Summit Therapeutics plc (SMMT) was down -4.86% during the last trading session, with a day high of 9.18. 3473 shares were traded on Summit Therapeutics plc's last session. The stock's 50 day moving average is 10.63 and its 200 day ...
01/19/16 06:15 AMGrant of Key European Patent for Novel Antibiotic Ridinilazole for Treatment of CDI - [at noodls] - 21ef4c56-41a6-4d53-bdd3-d2f650504d86.pdf Summit Therapeutics plc ("Summit" or "the Company") SUMMIT THERAPEUTICS GRANTED KEY EUROPEAN PATENT FOR NOVEL ANTIBIOTIC RIDINILAZOLE FOR TREATMENT ...
01/19/16 06:00 AMSummit Therapeutics Granted Key European Patent for Novel Antibiotic Ridinilazole for Treatment of C. Difficile Infection - [GlobeNewswire] - OXFORD, UK, Jan. 19, 2016-- Summit Therapeutics plc, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that the ...
01/14/16 03:34 AMSummit Therapeutics Plc breached its 50 day moving average in a Bearish Manner : January 14, 2016 -
12/17/15 06:07 AMQ3 2016 Summit Therapeutics PLC Earnings Release - Time Not Supplied -

Social

About Summit Therapeutics PLC

Summit Therapeutics PLC logoSummit Therapeutics plc, formerly Summit Corporation plc, is a United Kingdom-based biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. The Company is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The Company's lead DMD product candidate is SMT C1100, an orally administered small molecule. The Company's lead CDI product candidate is SMT19969, an orally administered small molecule antibiotic. The Company subsidiaries include Summit Therapeutics, Inc., Summit (Oxford) Limited, Summit (Wales) Limited and MuOx Limited, among others.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: SUMM
  • CUSIP:
Key Metrics:
  • Previous Close: $1.36
  • 50 Day Moving Average: $106.35
  • 200 Day Moving Average: $111.52
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $62.86M
  • Current Year EPS Consensus Estimate: $-38.24 EPS
  • Next Year EPS Consensus Estimate: $N/A EPS
Additional Links: